Baader Bank Aktiengesellschaft Takes $373,000 Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Baader Bank Aktiengesellschaft purchased a new position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 28,000 shares of the company’s stock, valued at approximately $373,000. Baader Bank Aktiengesellschaft owned 0.11% of Eton Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ETON. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eton Pharmaceuticals during the third quarter worth about $54,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals during the 3rd quarter valued at approximately $90,000. Renaissance Technologies LLC lifted its holdings in Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after buying an additional 41,469 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after buying an additional 30,167 shares during the last quarter. Finally, Wasatch Advisors LP purchased a new position in shares of Eton Pharmaceuticals during the third quarter valued at approximately $1,431,000. Institutional investors own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ETON shares. HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. B. Riley began coverage on Eton Pharmaceuticals in a research report on Friday, January 10th. They set a “buy” rating and a $21.00 price objective on the stock. Finally, Craig Hallum increased their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $17.32 on Friday. Eton Pharmaceuticals, Inc. has a one year low of $3.03 and a one year high of $17.77. The business’s fifty day moving average is $13.37 and its 200 day moving average is $8.59. The stock has a market capitalization of $451.19 million, a PE ratio of -78.73 and a beta of 1.38.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.